


Product: Calphostin C

ALTERNATE NAME: (1*R*)-2-[12-[(2*R*)-2-(Benzoyloxy)propyl]-3,10-dihydro-4,9-dihydroxy-2,6,7,11-tetramethoxy-3,10-dioxo-1-perylenyl]-1-methylethylcarbonic acid 4-hydroxyphenyl esterUCN 1028C; PKF115-584; Cal-C

CATALOG #: 2611-50, 100

AMOUNT: 50 µg, 100 µg

STRUCTURE:

MOLECULAR FORMULA: C₄₄H₃₈O₁₄

MOLECULAR WEIGHT: 790.76

CAS No. 121263-19-2

APPEARANCE: Dark red solid

SOLUBILITY: DMSO (~ 1 mg/ml) or EtOH (~ 1 mg/ml)

PURITY: >95% by HPLC

STORAGE: Store at -20°C. Protect from air and light

DESCRIPTION: A potent and highly specific cell-permeable protein kinase C (PKC) inhibitor. The inhibition of PKC is light-dependent. Also inhibits PKA, PKG, DAG kinase, phospholipase D1 and D2, myosin light chain kinase and c-Src. Anticancer compound. Inhibits cell proliferation and strongly induces apoptosis *in vitro*. Shown to directly and potently block L-type calcium channels. Calphostin C specifically inhibits contraction-stimulated glucose transport but not insulin-stimulated glucose transport in skeletal muscle. Also Wnt/β-catenin/lef-1 signaling inhibitor.

REFERENCES: Pollack, I.F., and Kawecki, S. (1997). *J. Neurooncol.* **31**, 255-266.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

RELATED PRODUCTS:

Bisindolylmaleimide I (Cat. No. 1945-1, 5)
Bisindolylmaleimide I hydrochloride (Cat. No. 1947-1, 5)
Chelerythrine chloride (Cat. No. 2064-5)
Enzastaurin (Cat. No. 1619-1, 5)
Fasudil Mono HCl (Cat. No. 1787-10, 50)
Go6976 (Cat. No. 1711-500)
EZSolution™ Go6976 (Cat. No. 1785-500)
H-89 DiHCl (Cat. No. 1768-1, 5)
K252a (Cat. No. 2013-500, 1000)
KN-93, Water-Soluble (Cat. No. 1909-1, 5)
PKC412 (Cat. No. 2052-1,5)
Ro 31-8220 methanesulfonate (Cat. No. 1946-1, 5)
Staurosporine (Cat. No. 1048-01, 1)
EZSolution™ Staurosporine (Cat. No. 1745-01)
Stauprimide (Cat. No. 1743-500)
Tamoxifen citrate (Cat. No. 1551-1000)

FOR RESEARCH USE ONLY! Not to be used in humans.